摘要
目的观察顺铂联合重组人白介素-2胸腔灌注治疗恶性胸腔积液的临床疗效和毒副反应。方法回顾性分析我院自2013年8月~2015年8月61例恶性胸腔积液患者治疗情况,随机分为两组,A组31例,以顺铂联合重组人白介素-2胸腔灌注治疗,B组（30例）对照组,单以顺铂胸腔灌注治疗。结果胸水消退情况：A组有效率为83.9%（26/31）,B组为56.7%（17/30）,差异有统计学意义（P〈0.05）。两组之间的毒副反应均可以耐受,无明显不良反应。结论顺铂联合重组人白介素-2胸膜腔灌注治疗肺癌并恶性胸水有效率高,毒副反应小,治疗方便安全,不仅改善症状,而且提高了生活质量,可作为姑息治疗手段。
Objective To investigate the clinical effects and side effects of cisplatin plus recombinant human interleukin-2（rhil-2） for the treatment of malignant pleural effusion（MPE）. Methods A retrospective analysis of 61 MPE patients received treatment from August 2013 to August 2015. Sixtyone patients were randomly divided into treatment group（cisplatin plus rhil-2 via thoracic perfusion,n=31） and control group（n=30）. Results The effective rates of hydrothorax elimination in treatment group and control group were 83.9%（26/31） and 56.7%（17/30）,respectively（P〈0.05）. All the patients can bear the side effects with no significant severe reaction detected. Conclusion Cisplatin plus recombinant human interleukin-2 for the treatment of MPE showed less side effects and high effective rate,thus,it can be the preferred for the palliative treatment.
出处
《中国继续医学教育》
2016年第34期160-162,共3页
China Continuing Medical Education
